ORIC Pharmaceuticals Appoints Matt Panuwat as Chief Business Officer
November 26, 2018 at 08:33 am
Share
ORIC Pharmaceuticals announced that Matt Panuwat has been appointed Chief Business Officer. Mr. Panuwat will serve on the executive leadership team and will lead business and corporate development for ORIC. Prior to joining the company, Mr. Panuwat was Senior Vice President of Business Development at Prothena, where he led partnership activities and established the company's global research & development collaboration with Celgene.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.